Vyera and Martin Shkreli fail in bid to end Daraprim lawsuit
A federal judge in New York has ruled that Martin Shkreli and his company Vyera Pharmaceuticals must face an FTC lawsuit accusing them of scheming to maintain the company’s monopoly over antiparasitic drug Daraprim.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10